

FORM PTO-1449 (Modified)

Attorney Docket No.
015280-325100Serial No.: 09/918,867
09/071,672LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

Applicant: Susanna M. Rybak, et al.

Filing Date: May 1,
1998

Group: Unknown

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AO	AA	4,816,567	03/28/89	Cabilly, et al.	530	387
J	AB	5,559,212	09/24/96	Wojciech J. Ardelt	530	350
↓	AC	5,728,805	03/17/98	Wojciech J. Ardelt	530	350

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AD	EP 0 173 494 A2	07/08/85	Europe	C12N 15	00	Yes
AE	WO 87/02671	10/27/86	PCT	C07H 15	12	Yes
AF	WO 88/09344-A	05/19/88	PCT	C07K 13	00	Yes
AG	WO 97/02588	06/20/96	PCT	H01J 37	32	Yes
↓	AH	PCT/US98/05453 (as filed)	03/19/98	PCT		Yes

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	De Prisco, et al., "A Ribonuclease from human seminal plasma active on double-stranded RNA, <i>Biochim. Biophys. Acta</i> 788:356-363 (1984)
AJ	Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321:522-525 (5/29/86)
AK	Williams, et al., "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment" <i>Gene</i> 43:319-324 (1986)
AL	St. Clair, et al., "Angiogenin abolishes cell-free protein synthesis by specific ribonucleolytic inactivation of ribosomes," <i>Proc. Natl. Acad. Sci. USA</i> 84:8330-8334 (12/87)
AM	Riechmann, et al., "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327 (3/24/88)
AN	Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5878-5883 (8/88)
AO	Bird, et al., "Single-chain antigen-binding proteins," <i>Science</i> 242:423-426 (10/21/98)
AP	Darzynkiewicz, et al., "Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent," <i>Cell Tissue Kinet.</i> 21:169-182 (1988)
AQ	Khazaeli, et al., "Immunology," <i>Proceedings of AACR</i> 29:418 (1988)
AR	Nishimura, et al., "Expression and function of a CD 5 cDNA in human and murine T cells," <i>Eur. J. Immunol.</i> 18:747-753 (1988)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No. 015280-325100		Serial No.: 09/071,672-918867 <i>as</i>	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Susanna M. Rybak, et al.			
		Filing Date: May 1, 1998		Group: Unknown 1644	
Reference Designation		U.S. PATENT DOCUMENTS			
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>AS</i>	Griffin, et al., "Immunotoxin therapy: Assessment by animal models," <i>Immunotoxins</i> , Boston/Dordrecht/Lancaster, Kluwer Academic Publishers, p.433-455 (1988)				
AT	Chaudhary, et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <i>Nature</i> 339:394-397 (6/1/89)				
AU	Ward, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> 341:544-546 (10/12/89)				
AV	Batra, et al., "Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of <i>Pseudomonas</i> exotoxin," <i>Proc. Natl. Acad. Sci. USA</i> 86:8545-8549 (11/89)				
AW	Mikulski, et al., "Striking increase of survival of mice bearing M109 madison carcinoma treated with a novel protein from amphibian embryos," <i>J. Nat'l. Cancer Inst.</i> 82(2):151-153 (1/17/90)				
AX	Chaudhary, et al., "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. USA</i> 87:1066-1070 (2/90)				
AY	Casadei, et al., "Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector," <i>Proc. Natl. Acad. Sci. USA</i> 87:2047-2051 (3/90)				
AZ	Goodson, et al., "Site-directed pegylation of recombinant interleukin-2 at its glycosylation site," <i>Bio/Technology</i> 8:343-346 (4/90)				
BA	Batra, et al., "Anti-tac(Fv)-PE40, a single chain antibody <i>Pseudomonas</i> fusion protein directed at interleukin 2 receptor bearing cells," <i>J. Biol. Chem.</i> 265:15198-15202 (9/5/90)				
BB	Mikulski, et al., "Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumour activity," <i>Cell Tissue Kinet.</i> 23:237-246 (1990)				
BC	Winter, et al., "Man-made antibodies," <i>Nature</i> 349:293-299 (1/24/91)				
BD	Rybak, et al., "Human Cancer Immunology II. Clinical use of immunotoxins. Monoclonal antibodies conjugated to protein toxins," <i>Immunology and Allergy Clinics of North America</i> 11(2):359-380, W.B. Saunders Co. (5/91)				
BE	Pearson, J.W., et al., "Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by in vivo administration of MRK-16 monoclonal Antibody," <i>J. Natl. Cancer Inst.</i> 83(19):1386-1391 (10/2/91)				
<i>BF</i>	Ghetie, et al., "Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated Human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites," <i>Cancer Res.</i> 51:5876-5880 (11/1/91)				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Ann De Puma 1-21-93

FORM PTO-1449 (Modified)		Attorney Docket No. 015280-325100		Serial No.: 097071,672-09/918,887-00	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Susanna M. Rybak, et al.			
		Filing Date: May 1, 1998		Group: Unknown 1644	
Reference Designation		U.S. PATENT DOCUMENTS			
Examiner Initial	Document No.	Date	Name	Class	Sub-class
				Filing Date (If Appropriate)	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
<u>AM</u> BG	Hoogenboom, et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," <i>Molecular Immunology</i> 28(9):1027-1037 (11/4/91)				
BH	Rybak, et al., "Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins," <i>J. Biol. Chem.</i> 266:21202-21207 (11/5/91)				
BI	Hoogenboom, et al., "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule," <i>Biochim. Biophys. Acta</i> 1096:345-354 (11/20/91)				
BJ	Ardelt, et al., "Amino acid sequence of an anti-tumor protein from <i>Rana pipiens</i> oocytes and early embryos," <i>J. Biol. Chem.</i> 266(1):245-251 (1991)				
BK	Uckun, et al., "In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human Pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency," <i>Blood</i> 79(9):2201-2214 (5/1/92)				
BL	Newton, et al., "Cytotoxic ribonuclease chimeras," <i>J. Biol. Chem.</i> 267(27):19572-19578 (9/25/92)				
BM	Grossbard, et al., "Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms," <i>J. Clin. Oncol.</i> 11(4):726-737 (4/93)				
BN	Grossbard, et al., "Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma," <i>Blood</i> 81(9):2263-2271 (5/1/93)				
BO	Amlot, et al., "A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy," <i>Blood</i> 82(9):2624-2633 (11/1/93)				
BP	Rybak, et al. "Cytotoxic onconase and ribonuclease A chimeras: Comparison and in Vitro characterization," <i>Drug Delivery</i> 1:3-10 (1993)				
BQ	Newton, et al., "Toxicity of an antitumor ribonuclease to Purkinje neurons," <i>J. Neurosci.</i> 14(2):538-544 (2/94)				
BR	Rybak, et al., "RNase and RNase immunofusions for cancer therapy," <i>Tumor Targeting</i> 1(3):141-147 (1995)				
BS	Francisco, et al., "Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen," <i>Cancer Res.</i> 55:3099-3104 (7/15/95)				
BT	Sausville, et al., "Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A Phase I study," <i>Blood</i> 85(12):3457-3465 (6/15/95)				
BU	Mansfield, et al., "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies," <i>Bioconj. Chem.</i> 7:557-563 (1996)				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Am De Kim 1-21-03

FORM PTO-1449 (Modified)		Attorney Docket No. 015280-325100		Serial No.: 09/071,672 09/918,867	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Susanna M. Rybak, et al.			
		Filing Date: May 1, 1998		Group: Unknown 1644	
Reference Designation		U.S. PATENT DOCUMENTS			
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
<input checked="" type="checkbox"/> BV	Newton, D.L., et al., "Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo," <i>Int'l. Oncology</i> 8:1095-1104 (1996)				
<input type="checkbox"/> BW	Newton, D.L., et al., "Angiogenin single-chain immununofusions: influence of peptide linkers and spacers between fusion protein domains," <i>Biochemistry</i> 35:545-553 (1996)				
<input type="checkbox"/> BX	Mansfield, et al., "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors," <i>Blood</i> 90(5):2020-2026 (9/1/97)				
<input checked="" type="checkbox"/> BY	Mansfield, et al., "Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells," <i>Biochem. Soc. Trans.</i> 25:709-714 (1997)				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.WP 4/95

Amend 1-21-03

F:\DATA\PS\PTOD\SKF\88543.1